Federal government signs four contracts to develop Covid 19 drugs
The Swiss government has signed contracts with four Swiss-based companies to develop Covid-19 drugs. The total amount is approximately 27 million Swiss francs.
The four contracts on a Covid 19 drug solicitation are the result of an RFP the federal government issued in the summer of 2021 as part of its Covid 19 drug promotion program. has performed.
The total amount is around 27 million Swiss francs. The funding program will run until the end of 2022. It is intended to support the development of potentially important drugs to combat Covid-19. The contracts were signed with the following companies:
- GeNeuro SA, for the development of a monoclonal antibody to treat the long-term effects of Covid-19 (Long Covid) in patients suffering from severe neuropsychiatric symptoms;
- Kinarus AG, for the development of an oral combination therapy with antiviral and anti-inflammatory activity for all severities of Covid-19;
- Memo Therapeutics AG, for the development of an inhaled or intravenous monoclonal antibody for the treatment of infections with SARS-CoV-2, in patients at risk for a severe course of Covid-19;
- Noorik Biopharmaceuticals AG, for the development of an oral pulmonary vasodilator, to prevent respiratory failure and reduce the need for mechanical ventilation in the event of hospitalization due to Covid-19.
The new drugs are expected to be available by the end of 2022.
